Cargando…
Mesenchymal Stromal Cells as a Driver of Inflammaging
Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidenc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094085/ https://www.ncbi.nlm.nih.gov/pubmed/37047346 http://dx.doi.org/10.3390/ijms24076372 |
_version_ | 1785023753161277440 |
---|---|
author | Lyamina, Svetlana Baranovskii, Denis Kozhevnikova, Ekaterina Ivanova, Tatiana Kalish, Sergey Sadekov, Timur Klabukov, Ilya Maev, Igor Govorun, Vadim |
author_facet | Lyamina, Svetlana Baranovskii, Denis Kozhevnikova, Ekaterina Ivanova, Tatiana Kalish, Sergey Sadekov, Timur Klabukov, Ilya Maev, Igor Govorun, Vadim |
author_sort | Lyamina, Svetlana |
collection | PubMed |
description | Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidence showed that the majority of age-associated ailments, i.e., diabetes mellitus, cardiovascular diseases and neurodegeneration. These diseases are closely associated with tissue nonspecific inflammation triggered and controlled by mesenchymal stromal cell secretion. Mesenchymal stromal cells (MSCs) are known as the most common type of cells for therapeutic approaches in clinical practice. Side effects and complications of MSC-based treatments increased interest in the MSCs secretome as an alternative concept for validation tests in regenerative medicine. The most recent data also proposed it as an ideal tool for cell-free regenerative therapy and tissue engineering. However, senescent MSCs secretome was shown to hold the role of ‘key-driver’ in inflammaging. We aimed to review the immunomodulatory effects of the MSCs-secretome during cell senescence and provide eventual insight into the interpretation of its beneficial biological actions in inflammaging-associated diseases. |
format | Online Article Text |
id | pubmed-10094085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100940852023-04-13 Mesenchymal Stromal Cells as a Driver of Inflammaging Lyamina, Svetlana Baranovskii, Denis Kozhevnikova, Ekaterina Ivanova, Tatiana Kalish, Sergey Sadekov, Timur Klabukov, Ilya Maev, Igor Govorun, Vadim Int J Mol Sci Review Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidence showed that the majority of age-associated ailments, i.e., diabetes mellitus, cardiovascular diseases and neurodegeneration. These diseases are closely associated with tissue nonspecific inflammation triggered and controlled by mesenchymal stromal cell secretion. Mesenchymal stromal cells (MSCs) are known as the most common type of cells for therapeutic approaches in clinical practice. Side effects and complications of MSC-based treatments increased interest in the MSCs secretome as an alternative concept for validation tests in regenerative medicine. The most recent data also proposed it as an ideal tool for cell-free regenerative therapy and tissue engineering. However, senescent MSCs secretome was shown to hold the role of ‘key-driver’ in inflammaging. We aimed to review the immunomodulatory effects of the MSCs-secretome during cell senescence and provide eventual insight into the interpretation of its beneficial biological actions in inflammaging-associated diseases. MDPI 2023-03-28 /pmc/articles/PMC10094085/ /pubmed/37047346 http://dx.doi.org/10.3390/ijms24076372 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lyamina, Svetlana Baranovskii, Denis Kozhevnikova, Ekaterina Ivanova, Tatiana Kalish, Sergey Sadekov, Timur Klabukov, Ilya Maev, Igor Govorun, Vadim Mesenchymal Stromal Cells as a Driver of Inflammaging |
title | Mesenchymal Stromal Cells as a Driver of Inflammaging |
title_full | Mesenchymal Stromal Cells as a Driver of Inflammaging |
title_fullStr | Mesenchymal Stromal Cells as a Driver of Inflammaging |
title_full_unstemmed | Mesenchymal Stromal Cells as a Driver of Inflammaging |
title_short | Mesenchymal Stromal Cells as a Driver of Inflammaging |
title_sort | mesenchymal stromal cells as a driver of inflammaging |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094085/ https://www.ncbi.nlm.nih.gov/pubmed/37047346 http://dx.doi.org/10.3390/ijms24076372 |
work_keys_str_mv | AT lyaminasvetlana mesenchymalstromalcellsasadriverofinflammaging AT baranovskiidenis mesenchymalstromalcellsasadriverofinflammaging AT kozhevnikovaekaterina mesenchymalstromalcellsasadriverofinflammaging AT ivanovatatiana mesenchymalstromalcellsasadriverofinflammaging AT kalishsergey mesenchymalstromalcellsasadriverofinflammaging AT sadekovtimur mesenchymalstromalcellsasadriverofinflammaging AT klabukovilya mesenchymalstromalcellsasadriverofinflammaging AT maevigor mesenchymalstromalcellsasadriverofinflammaging AT govorunvadim mesenchymalstromalcellsasadriverofinflammaging |